Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hextar Healthcare BhdXKLS:7803 3-Year EBITDA Growth Rate is 30.20% as of Mar. 2026, which is 3079% above its 10-year median of 0.95. The stock has 3 warning signs investors should review. Among 1,409 Chemicals companies, Hextar Healthcare Bhd ranks better than 88.08% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 30.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Hextar Healthcare Bhd was 81.70% per year. The lowest was -23.50% per year. And the median was 0.95% per year.
Hextar Healthcare Bhd (XKLS:7803) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Hextar Healthcare Bhd 3-Year EBITDA Growth Rate Related Terms
XKLS:7803 vs LIN, SHW, ECL: 3-Year EBITDA Growth Rate Comparison
For the Specialty Chemicals subindustry, Hextar Healthcare Bhd's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hextar Healthcare Bhd 3-Year EBITDA Growth Rate vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Hextar Healthcare Bhd's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Hextar Healthcare Bhd's 3-Year EBITDA Growth Rate falls into.
Hextar Healthcare Bhd 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 30.20% mean?
Hextar Healthcare Bhd (XKLS:7803) has a 3-Year EBITDA Growth Rate of 30.20% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Hextar Healthcare Bhd and its competitors. This is 3079% above median its historical median of 0.95. According to the industry distribution chart, Hextar Healthcare Bhd ranks #168 out of 1409 companies in the Chemicals industry, placing it in the top 11.9%.
Is Hextar Healthcare Bhd's 3-Year EBITDA Growth Rate too high?
Hextar Healthcare Bhd's current 3-Year EBITDA Growth Rate of 30.20% is 3079% above median its 10-year median of 0.95. The Chemicals industry median 3-Year EBITDA Growth Rate is 0.80. Hextar Healthcare Bhd's value of 30.20% is 3675% above this industry median. Based on the distribution chart, Hextar Healthcare Bhd ranks #168 out of 1409 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers.
How does Hextar Healthcare Bhd's 3-Year EBITDA Growth Rate compare to LIN and SHW?
According to the Chemicals industry distribution chart, Hextar Healthcare Bhd ranks #168 out of 1409 companies for 3-Year EBITDA Growth Rate. This places Hextar Healthcare Bhd in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 0.80. Hextar Healthcare Bhd's value of 30.20% is 3675% above this benchmark. While the company's 10-year median is 0.95 vs. the industry median of 0.80, Hextar Healthcare Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Chemicals company?
The median 3-Year EBITDA Growth Rate among Chemicals companies is 0.80, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hextar Healthcare Bhd's current 3-Year EBITDA Growth Rate of 30.20% is 3675% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Hextar Healthcare Bhd and its competitors. For the Chemicals industry, the median 3-Year EBITDA Growth Rate is 0.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hextar Healthcare Bhd's current 3-Year EBITDA Growth Rate is 30.20%, which is 3079% above median its own 10-year median of 0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hextar Healthcare Bhd stock overvalued right now?
Based on GuruFocus' analysis, Hextar Healthcare Bhd (XKLS:7803) is currently considered Possible Value Trap. The stock's GF Value™ is RM0.15, compared to a current price of RM0.07 — trading 56.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 30.20%, which is 3079% above median its 10-year median of 0.95 and 3675% above the Chemicals industry median of 0.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Hextar Healthcare Bhd (XKLS:7803), the current 3-Year EBITDA Growth Rate is 30.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hextar Healthcare Bhd is principally involved in investment holding. Through its subsidiaries, it manufactures and sells rubber gloves. The company offers a wide range of industrial and safety gloves, household rubber gloves, and disposable vinyl and nitrile gloves. The company operates in three segments: Gloves operation, Medical devices operation, and Investment holding. The company generates the majority of its revenue from the Gloves operation segment. It has operations in Europe, Asia, North and South America, and the Rest of the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7803 has been successfully added to your 
